Abstract
Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m(2), including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent
Udgivelsesdato: 2008/11
Udgivelsesdato: 2008/11
| Original language | English |
|---|---|
| Journal | Magnetic Resonance Imaging Clinics of North America |
| Volume | 16 |
| Issue number | 4 |
| Pages (from-to) | 551-60, vii |
| ISSN | 1064-9689 |
| Publication status | Published - 2008 |
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS